Endoscopic Retrograde Cholangiopancreatography Market Size Worth USD 2892.49 Million by 2030 | MRFR

According to MRFR analysis, the global endoscopic retrograde cholangiopancreatography market size is projected to register a CAGR of 9.8% from 2022 to 2030 and hold a value of over USD 2,892.49 million by 2030.

Endoscopic Retrograde Cholangiopancreatography Market Highlights

Physical inactivity and a sedentary lifestyle trigger gastrointestinal diseases associated with the pancreaticobiliary duct system. Moreover, the increasing advancements through growth strategies and government support to improve the healthcare infrastructure in developing regions further create lucrative growth opportunities. Furthermore, the growing number of pediatric patients with pancreaticobiliary duct conditions, as well as the availability of trained pediatric physicians, aided endoscopic retrograde cholangiopancreatography market trends during the forecast period.

Regional Analysis

The North America market is projected to register the highest share during the forecast period. This is owing to several factors, including the presence of many patients suffering from intestinal diseases that may lead to pancreaticobiliary duct conditions, well-developed technology, high healthcare expenditure, and government support for research and development. Moreover, the rising prevalence of liver cancer among the Canadian population further supports market growth. According to the Canadian Cancer Society, 3,500 Canadians will have been diagnosed with liver cancer in 2022, with approximately 1,650 expected to die that year. Men are more likely than women to develop liver cancer. Hence, the increasing prevalence of pancreaticobiliary duct cancer and government support further propel the region's growth.

The Europe endoscopic retrograde cholangiopancreatography market share is attributed to show significant growth during the forecast period. This is due to the rising prevalence rate of gastrointestinal (GI) disorders, advanced healthcare infrastructure, the presence of favorable reimbursement policies, and the rising adoption of minimally invasive ERCP by patients.

The Asia-Pacific market is projected to have the fastest growth during the forecast period owing to the presence of a large patient pool and a rapidly growing elderly population base, which are the prime factors. As per the research, the increasing demand for ERCP devices in private hospitals and clinics is an opportunity for the market to flourish in countries like India and China.

Furthermore, the rest of the world comprises the Middle East, Latin America, and Africa. The rise in the prevalence of gastrointestinal disorders and cancer, the development of healthcare infrastructure, increasing healthcare spending, and the establishment of endoscopic training centers have driven the growth of the market. However, the limited awareness of cancer screening in Africa is expected to impede the market's growth.

Explore In-depth Details: Endoscopic Retrograde Cholangiopancreatography Market Research Report

Endoscopic Retrograde Cholangiopancreatography Market Segmentation 

The global endoscopic retrograde cholangiopancreatography market has been segmented into product, procedure, application, and end user.

Based on product, the market has been segmented into endoscopes, endotherapy devices, imaging devices, and energy devices. Endoscopes are projected to have the highest market share during the forecast period owing to a wide range of applications to diagnose and treat pancreaticobiliary duct conditions.

Based on procedure, the market has been segmented into biliary sphincterotomy, biliary stenting, biliary dilatation, pancreatic duct stenting, and others. The biliary sphincterotomy is expected to hold the highest share in 2021 owing to appropriate treatment of gallstones enabling them to pass quickly through intestine and further, this procedure mostly performed at ambulatory surgical center.

On the basis of application, the market has been segmented into bile duct, pancreas, and others. Bile duct segment is projected to have the largest market share in 2021, due to high incidence of bile duct conditions such as gallstones and primary biliary cholangitis.

Based on end users, the market has been segmented into hospitals & clinics, ambulatory surgical centers, and others. Hospitals & clinics are projected to have lucrative growth opportunities owing to the increasing number of ERCP and high adoption of advance technology in the hospitals & clinics.

Endoscopic Retrograde Cholangiopancreatography Market Key Players

Some of the key market players are Olympus Corporation (Japan), Fujifilm Holdings, Corporation (Japan), STERIS PLC (UK), Cook Medical (US), Boston Scientific Corporation (US), CONMED Corporation (US), HOYA Group (Japan), Q3 Medical Devices Limited (Ireland), Ambu Inc. (Denmark), Medtronic Plc (Ireland), and Others.